Patents by Inventor David Bumcrot

David Bumcrot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12145963
    Abstract: The present invention provides phenothiazine compounds, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment of various diseases or conditions, for example ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA).
    Type: Grant
    Filed: November 16, 2022
    Date of Patent: November 19, 2024
    Assignee: Camp4 Therapeutics Corporation
    Inventors: David A. Bumcrot, Alfica Sehgal, Donald L. Hertzog
  • Publication number: 20240360451
    Abstract: Described herein are methods of modulating OTC gene transcription using antisense oligonucleotides (ASOs) targeting regulatory RNAs, such as promoter-associated RNAs and enhancer RNAs. These methods are useful for increasing expression of Ornithine transcarbamylase (OTC), thereby treating diseases associated with aberrant gene expression.
    Type: Application
    Filed: September 2, 2022
    Publication date: October 31, 2024
    Inventors: Alfica Sehgal, Bryan J. Matthews, Cynthia M. Smith, David A. Bumcrot, Justin A. Caravella, Mario Esteban Contreras Gamboa, Rachana S. Kelkar, Yun Joon Jung, Yuting Liu, Subhadeep Roy, Brynn Nicole-Yoshiko Akerberg, Rutuja Sudhakar Pai
  • Publication number: 20240336924
    Abstract: Described herein are methods of modulating gene transcription using antisense oligonucleotides (ASOs) targeting regulatory RNAs, such as promoter-associated RNAs and enhancer RNAs. These methods are useful for modulating the levels of gene products, for example, increasing expression of Carbamoyl-Phosphatase Synthetase 1 (CPS1), thereby treating diseases associated with aberrant gene expression.
    Type: Application
    Filed: June 24, 2024
    Publication date: October 10, 2024
    Inventors: Alfica Sehgal, Bryan J. Matthews, David A. Bumcrot, Justin A. Caravella, Mario Esteban Contreras Gamboa, Rachana S. Kelkar, Yun Joon Jung, Yuting Liu, Rutuja Sudhakar Pai, Henry Munir Moukheiber, Subhadeep Roy, Yuchun Guo
  • Publication number: 20240309386
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the TMPRSS6 gene, and methods of using such dsRNA compositions to inhibit expression of TMPRSS6.
    Type: Application
    Filed: September 28, 2023
    Publication date: September 19, 2024
    Inventors: David Bumcrot, Brian Bettencourt, Ivanka Toudjarska
  • Publication number: 20240294917
    Abstract: CRISPR/CAS-related compositions and methods for treatment of HSV-1 are disclosed.
    Type: Application
    Filed: August 18, 2023
    Publication date: September 5, 2024
    Applicant: EDITAS MEDICINE, INC
    Inventors: Morgan L. Maeder, Ari E. Friedland, G. Grant Welstead, David A. Bumcrot
  • Publication number: 20240255880
    Abstract: The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpina1 gene, and methods of using such dsRNA compositions to inhibit expression of Serpina1.
    Type: Application
    Filed: August 29, 2023
    Publication date: August 1, 2024
    Inventors: Alfica Sehgal, David Bumcrot, Brian Bettencourt
  • Patent number: 12031133
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: July 9, 2024
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • Patent number: 11834649
    Abstract: CRISPR/CAS-related systems, compositions and methods for editing RS1, RL2, and/or LAT genes in human cells are described, as are cells and compositions including cells edited according to the same.
    Type: Grant
    Filed: April 19, 2021
    Date of Patent: December 5, 2023
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Ari E. Friedland, Penrose O'Donnell, David A. Bumcrot
  • Publication number: 20230295725
    Abstract: Compositions and methods for treatment of CEP290 related diseases are disclosed.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 21, 2023
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee MAEDER, Rina J. MEPANI, David A. BUMCROT, Shen SHEN, Michael STEFANIDAKIS
  • Publication number: 20230257410
    Abstract: The present invention provides phenothiazine compounds, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment of various diseases or conditions, for example ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA).
    Type: Application
    Filed: November 16, 2022
    Publication date: August 17, 2023
    Inventors: David A. Bumcrot, Alfica Sehgal, Donald L. Hertzog
  • Publication number: 20230038993
    Abstract: Compositions and methods for treatment of CEP290 related diseases are disclosed.
    Type: Application
    Filed: February 2, 2021
    Publication date: February 9, 2023
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee MAEDER, Rina J. MEPANI, David A. BUMCROT, Shen SHEN, Michael STEFANIDAKIS
  • Publication number: 20230026726
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Sickle Cell Disease (SCD) are disclosed.
    Type: Application
    Filed: February 7, 2022
    Publication date: January 26, 2023
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Ari E. FRIEDLAND, Morgan L. MAEDER, G. Grant WELSTEAD, David A. BUMCROT
  • Publication number: 20230025279
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Leber's Congenital Amaurosis 10 (LCA10) are disclosed.
    Type: Application
    Filed: March 7, 2022
    Publication date: January 26, 2023
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee MAEDER, David A. BUMCROT, Shen SHEN
  • Publication number: 20230002760
    Abstract: CRISPR/Cas-related compositions and methods which provide for efficient gene editing of eukaryotic cells using modified gRNAs.
    Type: Application
    Filed: January 10, 2022
    Publication date: January 5, 2023
    Inventors: Gordon Grant Welstead, Jennifer Leah Gori, Jack Michael Heath, David A. Bumcrot
  • Patent number: 11542290
    Abstract: The present invention provides phenothiazine compounds, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment of various diseases or conditions, for example ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA).
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: January 3, 2023
    Assignee: CAMP4 THERAPEUTICS CORPORATION
    Inventors: David A. Bumcrot, Alfica Sehgal, Donald L. Hertzog
  • Patent number: 11530408
    Abstract: This application relates to therapeutic siRNA agents and methods of making and using the agents.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: December 20, 2022
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, David Bumcrot
  • Publication number: 20220348915
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Application
    Filed: February 9, 2021
    Publication date: November 3, 2022
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • Publication number: 20220307083
    Abstract: The invention relates to methods and assays for determining the activity of a composition comprising a therapeutic gene administered to a subject.
    Type: Application
    Filed: February 14, 2022
    Publication date: September 29, 2022
    Inventors: Dinah Sah, David Bumcrot, Alfica Sehgal
  • Publication number: 20220273818
    Abstract: Compositions and methods for treatment of CEP290 related diseases are disclosed.
    Type: Application
    Filed: October 11, 2021
    Publication date: September 1, 2022
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee MAEDER, Rina J. MEPANI, David A. BUMCROT, Shen SHEN, Michael STEFANIDAKIS
  • Publication number: 20220251570
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the TMPRSS6 gene, and methods of using such dsRNA compositions to inhibit expression of TMPRSS6.
    Type: Application
    Filed: October 26, 2021
    Publication date: August 11, 2022
    Inventors: David Bumcrot, Brian Bettencourt, Ivanka Toudjarska